<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Kidney disease in HIV-infected patients.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;New York State Department of Health. Kidney disease in HIV-infected patients. New York (NY): New York State Department of Health; 2012 Sep. 21 p.  [54 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Anemia, unspecified  (285.9); Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diagnostic ultrasound of urinary system  (88.75); General physical examination  (89.7); Human immunodeficiency virus [HIV] disease  (042)"/><FieldValue Value="MSH: Anemia ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Anti-HIV Agents ; Anti-Inflammatory Agents, Non-Steroidal ; Anti-Retroviral Agents ; Biopsy ; Blood Urea Nitrogen ; Creatinine ; Diabetes Mellitus ; Dyslipidemias ; Glomerular Filtration Rate ; HIV Infections ; Hyperglycemia ; Hypertension ; Kidney Diseases ; Kidney Function Tests ; Medication Therapy Management ; Physical Examination ; Referral and Consultation ; Ultrasonography ; Urinalysis "/><FieldValue Value="MTH: Anemia ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Anti-Inflammatory Agents, Non-Steroidal ; Biopsy ; Blood urea nitrogen measurement ; Chronic Kidney Diseases ; Creatinine ; Creatinine measurement ; Diabetes Mellitus ; Glomerular Filtration Rate ; HIV Infections ; Hyperglycemia ; Hypertensive disease ; Kidney biopsy ; Kidney Diseases ; Kidney Function Tests ; Patient Monitoring ; physical examination ; Tenofovir ; Ultrasonography ; urinalysis ; Urine albumin/creatinine ratio measurement ; Urine total protein measurement "/><FieldValue Value="PDQ: anemia ; biopsies ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Anemia  (271737000); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Biopsy  (129314006); Biopsy  (86273004); Blood urea nitrogen measurement  (105011006); Blood urea nitrogen measurement  (250623007); Creatinine  (15373003); Creatinine measurement  (70901006); Diabetes mellitus  (73211009); Dyslipidemia  (370992007); Glomerular filtration rate  (80274001); Human immunodeficiency virus infection  (86406008); Hyperglycemia  (237598005); Hyperglycemia  (80394007); Hypertensive disorder  (38341003); Kidney biopsy  (7246002); Kidney disease  (90708001); Monitoring of patient  (182777000); Non-steroidal anti-inflammatory agent  (16403005); Non-steroidal anti-inflammatory agent  (372665008); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Referral to nephrologist  (306286007); Renal function study  (44277000); Tenofovir  (395264002); Tenofovir  (422091007); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005); Ultrasonography of urinary system  (303917008); Ultrasonography of urinary system  (77658008); Urinalysis  (167217005); Urinalysis  (27171005); Urine albumin/creatinine ratio measurement  (271075006); Urine total protein measurement  (270999004)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC "/><FieldValue Value="UMD: Scanning Systems, Ultrasonic  (14-278)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;July 9, 2015 - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDS)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on FDA&amp;rsquo;s comprehensive review of new safety information, FDA is requiring updates to the drug labels of all prescription NSAIDs. As is the case with current prescription NSAID labels, the Drug Facts labels of over-the-counter (OTC) non-aspirin NSAIDs already contain information on heart attack and stroke risk. FDA will also request updates to the OTC non-aspirin NSAID Drug Facts labels. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus-associated nephropathy (HIVAN) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute renal failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Membranoproliferative glomerulonephritis (MPGN) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Family Practice" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Clinical Laboratory Personnel" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To develop guidelines for diagnosis and management of kidney disease in human immunodeficiency virus (HIV)-infected patients&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Human immunodeficiency virus (HIV)-infected patients at risk of or diagnosed with kidney disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Diagnosis/Evaluation/Initial Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient education about human immunodeficiency virus (HIV) and kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine screening assessment of kidney function&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Glomerular filtration rate (GFR) estimated from serum creatinine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood urea nitrogen &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Urinalysis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Calculation of urine albumin-to-creatinine ratio in patients with diabetes &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diagnostic evaluation of kidney function&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Urinalysis to screen for cells and cellular casts &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Quantification of urinary protein excretion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Renal sonogram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Careful physical examination &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to nephrologist when disease progression indicates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney biopsy &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antiretroviral therapy (ART) to prevent progression of kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful monitoring of kidney function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nephrologist consultation, as needed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of comorbid hyperglycemia, dyslipidemia, anemia, and hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;HIV-related medication dosage adjustments in the setting of renal complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Special considerations for patients receiving tenofovir-containing regimens &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessing patients for use of nonsteroidal anti-inflammatory drugs &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevalence of acute renal failure and chronic renal disease among human immunodeficiency virus (HIV)-infected patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effect of antiretroviral therapy on survival rate and kidney function in patients with HIV-associated nephropathy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;MEDLINE was searched through May 2012 using key words appropriate to the topic. Available guidelines from the National Kidney Foundation on kidney disease that did not specifically pertain to HIV infection were also reviewed. Additionally, National Institutes of Health annual data reports on chronic kidney disease and end-stage renal disease, and administrative and cohort data published on the subject were used to consider disease estimates.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus (Committee)" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence for Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;One or more randomized trials with clinical outcomes and/or validated laboratory endpoints &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One or more well-designed, non-randomized trials or observational cohort studies with long-term clinical outcomes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;AIDS Institute clinical guidelines are developed by distinguished committees of clinicians and others with extensive experience providing care to people with HIV infection. Committees* meet regularly to assess current recommendations and to write and update guidelines in accordance with newly emerging clinical and research developments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Committees* rely on evidence to the extent possible in formulating recommendations. When data from randomized clinical trials are not available, Committees rely on developing guidelines based on consensus, balancing the use of new information with sound clinical judgment that results in recommendations that are in the best interest of patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;* Current committees include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medical Care Criteria Committee &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Committee for the Care of Children and Adolescents with HIV Infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dental Standards of Care Committee &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mental Health Guidelines Committee &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Committee for the Care of Women with HIV Infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Committee for the Care of Substance Users with HIV Infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physicians' Prevention Advisory Committee &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacy Advisory Committee &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation for the statement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate recommendation for the statement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optional recommendation&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All guidelines developed by the Committee are externally peer reviewed by at least two experts in that particular area of patient care, which ensures depth and quality of the guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The quality of evidence &lt;strong&gt;(I-III)&lt;/strong&gt; and strength of recommendation &lt;strong&gt;(A-C)&lt;/strong&gt; are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Introduction&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Key Points&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Key Point&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Human immunodeficiency virus (HIV)-infected black patients with chronic kidney disease (CKD) have a significantly higher risk for end-stage renal disease (ESRD) compared with HIV-infected white patients with CKD.&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Patient Education about Kidney Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should educate patients about the following &lt;strong&gt;(BIII)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The association between HIV and kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The role of antiretroviral therapy (ART) in prevention of HIV-associated nephropathy (HIVAN) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Importance of routine monitoring appointments to assess for other causes of kidney disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Renal Syndrome and Risk Factors for Kidney Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Appendix A and Appendix B in the original guideline document for information about the reported prevalence of acute renal failure (ARF) and the reported prevalence of CKD, respectively.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Routine Kidney Disease Screening: Laboratory Assessment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should routinely assess kidney function in all HIV-infected patients. A renal assessment should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Glomerular filtration rate (GFR) estimated from serum creatinine (baseline and at least every 6 months) &lt;strong&gt;(AII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood urea nitrogen (baseline and at least every 6 months) &lt;strong&gt;(AIII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urinalysis (baseline and at least annually) &lt;strong&gt;(AIII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients with diabetes and no known proteinuria: calculation of urine albumin-to-creatinine ratio to detect microalbuminuria (baseline and at least annually) &lt;strong&gt;(AI)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;For patients receiving a tenofovir-containing regimen, clinicians should estimate glomerular filtration rate at initiation of therapy, 1 month after initiation of therapy, and at least every 4 months thereafter.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Glomerular Filtration Rate&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Important Limitations to Calculating GFR&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Unlike the Chronic Kidney Disease Epidemiology Consortium (CKD-EPI), the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault have not been validated in people with normal kidney function and do not accurately estimate GFR in the normal range; therefore, when GFR is &amp;gt;60 mL/min, small but possibly meaningful changes in GFR that may indicate early kidney disease cannot be reliably measured with the MDRD and Cockcroft-Gault equations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All of these equations have diminished accuracy in patients with extremes of body weight, such as body builders, amputees, and frail individuals; for these patients, a 24-hour creatinine clearance may be a better test because serum creatinine within the normal range may not correlate with a normal GFR. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Key Points&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Key Points&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;The MDRD or CKD-EPI, not the Cockcroft-Gault, equations are used by clinical laboratories when reporting estimated GFR from serum creatinine; however, drug manufacturers' recommended dose adjustments for kidney function are based on the Cockcroft-Gault equation, not the MDRD.&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;For MDRD and CKD-EPI calculators, refer to &lt;a href=&quot;http://mdrd.com/&quot; title=&quot;MDRD Calculator Web site&quot;&gt;http://mdrd.com&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;For Cockcroft-Gault, refer to &lt;a href=&quot;http://nephron.com/cgi-bin/CGSI.cgi&quot; title=&quot;Nephron Web site&quot;&gt;http://nephron.com/cgi-bin/CGSI.cgi&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The CKD-EPI equation has begun to replace the MDRD equation when clinical laboratories report GFR. Unlike the other equations, the CKD-EPI equation has been validated in individuals with normal kidney function of &amp;gt;60 mL/min, although this has not been studied in the setting of HIV infection. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Urine Protein Excretion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Key Points&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Key Point&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Microscopic hematuria and mild proteinuria (urinary protein excretion &amp;lt;1500 mg/day) are generally asymptomatic. They have little clinical impact alone but can indicate an early stage of a serious disease, such as acute or chronic glomerular disease. A kidney biopsy is often deferred in such circumstances until the renal disease progresses, as manifested by increasing proteinuria, decreasing GFR, or the development of hypertension.&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Diagnosis and Evaluation of Kidney Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients with borderline glomerular filtration rate, regardless of age, should undergo the following diagnostic evaluation of kidney function &lt;strong&gt;(AII)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Urinalysis to screen for cells and cellular casts &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quantification of urinary protein excretion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Renal sonogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful physical examination &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Primary care clinicians should refer patients to a nephrologist when &lt;strong&gt;(AII)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The diagnosis is uncertain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney disease is progressing rapidly &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stage 4 to 5 chronic kidney disease is present (see Table 1 in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney biopsy is being considered &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Key Points&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Key Point&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;As CKD progresses, more pronounced signs or symptoms may appear, including increased blood pressure, anemia, or edema (mild to severe). All forms of CKD have the potential to progress to ESRD.&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis of HIV Associated Nephropathy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In circumstances when a kidney biopsy is not performed for an HIV-infected patient with kidney dysfunction, because of contraindication, clinician judgment, or patient preference, the following diagnostic criteria for HIV-associated nephropathy are reasonable &lt;strong&gt;(BIII)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;No other explainable cause(s) of kidney disease &lt;em&gt;and&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Proteinuria of &amp;gt;2000 mg &lt;em&gt;and&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Normal to large echogenic kidneys on sonogram &lt;em&gt;and&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Black race &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;For patients with empirically diagnosed HIV-associated nephropathy whose kidney disease worsens after initiation of ART, a biopsy should be performed to determine the underlying cause. &lt;strong&gt;(AIII)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Management of Kidney Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with low-grade proteinuria and/or slightly decreased glomerular filtration rate should receive ART if not already receiving it, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and careful monitoring of kidney function.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should consult with a nephrologist when managing patients who are approaching end-stage renal disease due to stage 4 to 5 chronic kidney disease (see Table 1 in the original guideline document) and require special interventions for hyperparathyroidism, anemia, hemodialysis vascular access, peritoneal dialysis, and/or kidney transplant options. &lt;strong&gt;(AII)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Use of ART to Prevent Progression of Kidney Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should educate patients with HIV-associated nephropathy about the increased urgency of initiating ART (see the National Guideline Clearinghouse [NGC] summary of the New York State Department of Health [NYSDOH] guideline &lt;a href=&quot;/content.aspx?id=48157&quot; title=&quot;Guideline #10394&quot;&gt;Antiretroviral Therapy&lt;/a&gt;: Section III: Deciding When to Initiate ART). &lt;strong&gt;(AII)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Comorbid Hyperglycemia, Dyslipidemia, Anemia, and Hypertension&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should treat hyperglycemia, dyslipidemia, anemia, and hypertension in HIV-infected patients with kidney disease according to standard guidelines for non-HIV-infected patients. &lt;strong&gt;(AI)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;HIV-infected normotensive patients with kidney disease should receive angiotensin-converting enzyme inhibitors or angiotensin receptor blockers according to standard guidelines for non-HIV-infected patients. &lt;strong&gt;(AI)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management Considerations Requiring Referral to a Nephrologist&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should refer HIV-infected patients with kidney disease to a nephrologist when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Considering management with steroids, immunosuppression, hemodialysis, or transplantation &lt;strong&gt;(AIII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A diagnosis of membranoproliferative glomerulonephritis has been made for HIV/hepatitis C virus (HCV) co-infected patients &lt;strong&gt;(AIII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;HIV-Related Medication Adjustments in the Setting of Renal Complication&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should determine whether dose adjustments are required for certain antiretroviral agents or whether patients should avoid use of certain agents when glomerular filtration rate reaches &amp;le;50 mL/min; recommendations for such considerations are provided in the table below. &lt;strong&gt;(AIII)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Table: Recommended ART Dose Adjustments at GFR Less than or Equal to 50 mL/min&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Table: Recommended ART Dose Adjustments at GFR &amp;le;50 mL/min&lt;sup&gt;a&lt;/sup&gt;&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Nucleoside/Nucleotide Reverse Transcriptase Inhibitors&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Zidovudine &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Adjust dose if creatinine clearance reaches &amp;le;15 mL/min &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Didanosine&lt;sup&gt;b&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Emtricitabine &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lamivudine &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stavudine &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Tenofovir&lt;sup&gt;c&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Adjust dose if creatinine clearance reaches &amp;le;50 mL/min &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Avoid or use with caution when didanosine is co-administered with tenofovir in renal failure &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;CCR5 Co-Receptor Agonists&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Maraviroc &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Adjust dose if creatinine clearance reaches &amp;lt;30 mL/min and patient experiences postural hypotension &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Co-Formulated Agents&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Combivir (lamivudine + zidovudine) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Epzicom (abacavir + lamivudine) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Trizivir (abacavir + lamivudine + zidovudine) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Atripla (efavirenz + emtricitabine + tenofovir&lt;sup&gt;c&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Complera (emtricitabine + rilpivirine + tenofovir&lt;sup&gt;c&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stribild&lt;sup&gt;d&lt;/sup&gt; (elvitegravir + cobicistat + emtricitabine + tenofovir&lt;sup&gt;c&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Do not use if creatinine clearance reaches &amp;lt;50 mL/min &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Individual components should be administered with appropriate dose adjustments &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Truvada (emtricitabine + tenofovir&lt;sup&gt;c&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Do not use if creatinine clearance reaches &amp;lt;30 mL/min&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt; Clinicians should refer to prescribing information for individual agents when a patient has reduced GFR.&lt;/p&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;b&lt;/sup&gt; The manufacturer recommends adjustment at &amp;le;60 mL/min for didanosine; however, adjustment at &amp;le;50 mL/min is a reasonable approach.&lt;/p&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;c&lt;/sup&gt; Alternative antiretroviral agents should be considered in patients with renal insufficiency.&lt;/p&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;d&lt;/sup&gt; Avoid use in patients with creatinine clearance of &amp;lt;70 mL/min at initiation of treatment.&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tenofovir&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients receiving tenofovir-containing regimens, clinicians should:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Estimate glomerular filtration rate at initiation of therapy, 1 month after initiation of therapy, and at least every 4 months thereafter &lt;strong&gt;(BII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adjust tenofovir dosing when glomerular filtration rate approaches 50 mL/min or discontinue tenofovir according to clinical status &lt;strong&gt;(AII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Withhold tenofovir until all potential causes have been determined in patients who develop acute renal failure &lt;strong&gt;(BII)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Nonsteroidal Anti-inflammatory Drugs&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinicians should assess for use of nonsteroidal anti-inflammatory drugs in HIV-infected patients with declining renal function. Decisions about the use of such agents for these patients should be individualized and patients should be educated about the importance of using these drugs with caution. &lt;strong&gt;(BII)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence for Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;One or more randomized trials with clinical outcomes and/or validated laboratory endpoints &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One or more well-designed, non-randomized trials or observational cohort studies with long-term clinical outcomes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation for the statement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate recommendation for the statement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optional recommendation &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm is provided in the original guideline document for &quot;Steps for screening and initial management of kidney disease.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate diagnosis, management and prevention of kidney disease in human immunodeficiency virus (HIV)-infected patients&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Tenofovir is associated with renal dysfunction. It should be dose-adjusted according to glomerular filtration rate (GFR) or discontinued according to clinical status. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of nonsteroidal anti-inflammatory drugs (NSAIDs) may exacerbate kidney disease. NSAID use should be assessed, and these agents should be used with caution in the setting of declining renal function. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should be aware of the potential for significant drug-drug interactions between antiretroviral therapy (ART) and immunosuppressive agents. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Tenofovir is relatively contraindicated as an initial regimen in patients with preexisting kidney disease and glomerular filtration rate (GFR) levels near 50 to 60 mL/min. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Concomitant use of nephrotoxic agents should be avoided in patients with renal dysfunction. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When formulating guidelines for a disease as complex and fluid as human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), it is impossible to anticipate every scenario. It is expected that in specific situations, there will be valid exceptions to the approaches offered in these guidelines and sound reason to deviate from the recommendations provided within.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The AIDS Institute's Office of the Medical Director directly oversees the development, publication, dissemination and implementation of clinical practice guidelines, in collaboration with The Johns Hopkins University, Division of Infectious Diseases. These guidelines address the medical management of adults, adolescents and children with human immunodeficiency virus (HIV) infection; primary and secondary prevention in medical settings; and include informational brochures for care providers and the public.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Guidelines Dissemination&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guidelines are disseminated to clinicians, support service providers and consumers through mass mailings and numerous AIDS Institute-sponsored educational programs. Distribution methods include the HIV Clinical Resource website, the Clinical Education Initiative (CEI), the AIDS Educational Training Centers (AETC) and the HIV/AIDS Materials Initiative. Printed copies of clinical guidelines are available for order from the New York State Department of Health (NYSDOH) Distribution Center for providers who lack internet access.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Guidelines Implementation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The HIV Clinical Guidelines Program works with other programs in the AIDS Institute to promote adoption of guidelines. Clinicians, for example, are targeted through the CEI and the AETC. The CEI provides tailored educational programming on site for health care providers on important topics in HIV care, including those addressed by the HIV Clinical Guidelines Program. The AETC provides conferences, grand rounds and other programs that cover topics contained in AIDS Institute guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Support service providers are targeted through the HIV Education and Training initiative which provides training on important HIV topics to non-physician health and human services providers. Education is carried out across the State as well as through video conferencing and audio conferencing.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The HIV Clinical Guidelines Program also works in a coordinated manner with the HIV Quality of Care Program to promote implementation of HIV guidelines in New York State. By developing quality indicators based on the guidelines, the AIDS Institute has created a mechanism for measurement of performance that allows providers and consumers to know to what extent specific guidelines have been implemented.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Finally, best practices booklets are developed through the HIV Clinical Guidelines Program. These contain practical solutions to common problems related to access, delivery or coordination of care, in an effort to ensure that HIV guidelines are implemented and that patients receive the highest level of HIV care possible.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;New York State Department of Health. Kidney disease in HIV-infected patients. New York (NY): New York State Department of Health; 2012 Sep. 21 p.  [54 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 Sep" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="New York State Department of Health - State/Local Government Agency [U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;New York State Department of Health&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medical Care Criteria Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Committee Chair&lt;/em&gt;: Judith A Aberg, MD, New York University School of Medicine, New York, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Committee Vice-Chair&lt;/em&gt;: Samuel T Merrick, MD, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Members&lt;/em&gt;: Bruce D Agins, MD, MPH, New York State Department of Health, AIDS Institute, New York, New York; Barbara Chaffee, MD, MPH, United Health Services, Binghamton, New York; Steven M Fine, MD, PhD, University of Rochester Medical Center, Rochester, New York; Barbara E Johnston, MD, Mount Sinai Comprehensive Health Program-Downtown, New York, New York; Jessica E Justman, MD, Mailman School of Public Health, Columbia University, New York, New York; Jason M Leider, MD, PhD, North Bronx Healthcare Network of Jacobi and North Central Bronx Hospitals, Bronx, New York; Joseph P McGowan, MD, FACP, North Shore University Hospital, Manhasset, New York; Rona M Vail, MD, Callen-Lorde Community Health Center, New York, New York; Barry S Zingman, MD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;AIDS Institute Staff Liaison&lt;/em&gt;: Demetre C Daskalakis, MD, Bellevue Hospital, NYU Langone Medical Center, New York, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;AIDS Institute Staff Physicians&lt;/em&gt;: Charles J Gonzalez, MD, New York State Department of Health, AIDS Institute, New York, New York; Cheryl A Smith, MD, New York State Department of Health, AIDS Institute, New York, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Department of Veterans Affairs Medical Center Liaison&lt;/em&gt;: Sheldon T Brown, MD, James J Peters Veteran Affairs Medical Center, Bronx, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Medical Society of the State of New York Liaison&lt;/em&gt;: William Valenti, MD, FIDSA, University of Rochester School of Medicine, Rochester, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;New York City Department of Health and Mental Hygiene Liaison&lt;/em&gt;: Blayne Cutler, MD, PhD, New York City Department of Health and Mental Hygiene, Long Island City, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;New York City Health and Hospitals Corporation Liaison&lt;/em&gt;: Joseph R Masci, MD, Elmhurst Hospital Center, Elmhurst, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;New York State Department of Correctional Services Liaisons&lt;/em&gt;: Douglas G Fish, MD, Albany Medical College, Albany, New York; Carl J Koenigsmann, MD, New York State Department of Correctional Services, Albany, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pharmacy Advisory Committee Liaison&lt;/em&gt;: John M Conry, PharmD, BCPS, AAHIVP, Saint John's University, Queens, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;HIV Quality of Care Advisory Committee Liaison&lt;/em&gt;: Peter G Gordon, MD, Columbia University College of Physicians, and Surgeons, New York, New York&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Principal Investigator&lt;/em&gt;: John G Bartlett, MD, Johns Hopkins University, School of Medicine, Baltimore, Maryland&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.hivguidelines.org/clinical-guidelines/adults/kidney-disease-in-hiv-infected-patients/&quot; title=&quot;New York State Department of Health AIDS Institute Web site&quot;&gt;New York State Department of Health AIDS Institute Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preventing and managing kidney disease in HIV-infected patients. CME course. Available from the &lt;a href=&quot;http://www.ceitraining.org/resources/audio-video-detail.cfm?mediaID=174&amp;amp;cme=1&quot; title=&quot;Clinical Education Initiative Web site&quot;&gt;Clinical Education Initiative Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney and liver transplantation in people with HIV. Video. Available from the &lt;a href=&quot;http://www.ceiconnect.org/p83212541/?launcher=false&amp;amp;fcsContent=true&amp;amp;pbMode=normal&quot; title=&quot;Clinical Education Initiative Web site&quot;&gt;Clinical Education Initiative Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on February 21, 2013. This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the guideline developer. See the &lt;a href=&quot;http://www.hivguidelines.org/terms-of-usage/&quot; title=&quot;New York State Department of Health AIDS Institute Web site&quot;&gt;New York State Department of Health AIDS Institute Web site&lt;/a&gt; for terms of use.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
